In the same study, all patients without residual DVT after 6 months of LMWH stopped therapy and had a low risk of recurrence during the next year (three episodes in 91 patients). This study s ndings have not changed our recommendations for treatment of VTE in patients with cancer. Evaluations of Extended Anticoagulant Therapy Since AT9: When AT9 was written, extended treatment of VTE with VKA therapy had been evaluated in six studies (mostly patients with unprovoked proximal DVT or PE46,61-64 or a second episode of VTE65 ), and with an NOAC (rivaroxaban vs placebo) in one study of Since AT9, no studies have compared extended VKA therapy with stopping anticoagulants, although the large reduction in recurrent VTE with 18 additional months of VKA therapy compared with placebo (ie, before study drug was stopped) in the PADIS study60 supports AT9 estimates for the ef cacy of extended VKA therapy. Since AT9, two additional studies have compared extended NOAC therapy (dabigatran,47 ) with stopping treatment (ie, placebo). These two studies, and the previous study that evaluated extended treatment with rivaroxaban, found that extended therapy with these three NOAC regimens reduced recurrent VTE by at least 80% and was associated with a modest risk of bleeding (Tables 8-10, e-Tables 10-12).49 These three studies, however, enrolled heterogeneous populations of patients (ie, not con ned to unprovoked VTE) and only followed patients for 6 to 12 months, which limits the implications of their ndings in relationship to extended therapy. When considering the risks and bene ts of extended anticoagulation in this update, the AT10 panel decided TABLE 12 ] Summary of Findings: 6, 12, or 24 mo vs 3 or 6 mo as Minimum Duration of Anticoagulation for VTEa,b Outcomes No. 